ReviewViruses2022
Prevention of Herpes Zoster: A Focus on the Effectiveness and Safety of Herpes Zoster Vaccines.
Review in Viruses, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.
- Vaccines for preventing herpes zoster in older adults.The Cochrane database of systematic reviews · 2023Pooled it
- TLR9 and STING agonists adjuvanted varicella-zoster virus glycoprotein E induced a potent and durable nasal vaccine response.Human vaccines & immunotherapeutics · 2026Article
- Shingles: 10-year evolution of patient characteristics, clinical manifestations, therapeutic approach and complications.Skin health and disease · 2026Article
- Severe Disseminated Varicella Zoster in an Immunocompetent Adolescent: A Case Report.Clinical medicine insights. Pediatrics · 2026Article
- Herpes Zoster and Frailty in Older Adults: a Systematic Review.Canadian geriatrics journal : CGJ · 2026Review
- Article
- Epidemiology and risk factors of postherpetic neuralgia worldwide: protocol for a systematic review and meta-analysis.BMJ open · 2026Article
- Incidence of herpes zoster in Afro-descendant populations: a systematic literature review.BMJ public health · 2026Article
- Real-world study: Analysis of post-marketing safety for recombinant zoster vaccine in Shandong, China.Human vaccines & immunotherapeutics · 2025Article
- Surveillance on the coverage of herpes zoster vaccine and post-marketing adverse events in Jiangsu province, China.Human vaccines & immunotherapeutics · 2025Article
- Small Molecule Compounds Inhibit Varicella-Zoster Virus Replication by Targeting the Portal Protein-Capsid Interface.Viruses · 2025Article
- From Awareness to Action: Addressing Knowledge Barriers and Promoting Herpes Zoster Vaccination in Chinese Rheumatic Disease Patients.Vaccines · 2025Article
- Article
- Seroprevalence of Varicella-Zoster Virus and the Need for Herpes Zoster Vaccination Among Adults in Saudi Arabia.Cureus · 2025Article
- Herpes Zoster: Risk Factors for Occurrence, Complications, and Recurrence with a Focus on Immunocompromised Patients.Diseases (Basel, Switzerland) · 2025Review
- A successful diagnostic case of Varicella zoster virus pneumonia by a Film Array assay for meningitis/encephalitis.Respiratory medicine case reports · 2025Article
- Public Awareness and Willingness to Vaccinate Against Herpes Zoster: A Nationwide Cross-Sectional Study in Poland.Vaccines · 2024Article
- Article
- Article
- Herpes Zoster Recurrence: A Narrative Review of the Literature.Dermatology and therapy · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Infection with varicella zoster virus typically occurs in children and it can cause primary varicella infection or "chickenpox", or it can reactivate later in life and cause herpes zoster or "shingles". Herpes zoster mainly occurs in older adults, causing a reduction in activities of daily living, impacting quality of life, and may lead to serious complications, including chronic pain. Two vaccines are marketed to prevent herpes zoster: the live zoster vaccine and the non-live, recombinant zoster vaccine. The pre-licensure clinical trials show the efficacy of the live zoster vaccine to be between 50 and 70% and for the recombinant vaccine to be higher at 90 to 97%. Real-world effectiveness studies, with a follow-up of approximately 10 years, were reviewed in this article. These data corroborated the efficacy studies, with vaccine effectiveness being 46% and 85% for the live and recombinant vaccines, respectively. Safety data from the effectiveness studies show similar results to the clinical trials with mostly local injection-site reactions and mild systemic reactions seen with both vaccines, although in larger proportions with the recombinant vaccine. Rare adverse events, occurring less than 1% of the time, have been seen with both vaccine types and include disseminated herpes zoster with the live zoster vaccine and Guillain-Barré syndrome with the recombinant vaccine. The wider use of preventative measures with vaccines will reduce the herpes zoster burden of illness seen in older adults.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.